Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Eris Lifesciences Limited (ERIS.NS)
INR1,459.70
+6.60 (+0.45%)
IN NSE Healthcare Drug Manufacturers - Specialty & Generic
Address
Shivarth Ambit 380054
Ahmedabad, GU, IN
Ahmedabad, GU, IN
CEO
Amit Indubhushan Bakshi
Website
eris.co.in
IPO
2017-06-30
ISIN INE406M01024
Also trades on
Bombay Stock Exchange · ERIS.BO (INR)
National Stock Exchange of India · ERIS.NS (INR)
Description
Eris Lifesciences Limited is an Indian pharmaceutical company engaged in the manufacturing, marketing, and distribution of medicinal products throughout the country. The company provides a comprehensive range of branded formulations, catering to a wide spectrum of therapeutic areas. These encompass cardiovascular health, anti-diabetic treatments, anti-infectives, antipyretics, vitamin/nutrient supplements, gastroenterology, respiratory care, gynecology, pediatrics, neurology, psychiatry, and pain/analgesics, alongside services in in-vitro fertilization, cosmetology, and dermatology. Founded in 2007, Eris Lifesciences Limited is headquartered in Ahmedabad, India.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
INR1,459.70
+6.60 (+0.45%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
128.0K
Beta
-0.11
Float Shares
43.58M
Free Float %
31.4%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.72% | +0.63% | -1.46% | -1.93% | -18.07% | -10.10% | -12.19% | +117.67% | +91.27% | +125.02% | +125.02% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
1,459.70
DCF (Unlevered)
3,202.52
+119.4%
DCF (Levered)
1,092.37
-25.2%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
90% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 8 | 0 |
| Hold | 1 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
3.93
Safe zone
Piotroski F-Score
4 / 9
Average
MOAT Score
6 / 10
Developing
Composite Rating
A-
Overall Score
4 / 5
High
DCF Score
4 / 5
High
ROE Score
5 / 5
High
ROA Score
5 / 5
High
D/E Score
2 / 5
Medium
P/E Score
2 / 5
Medium
P/Book Score
2 / 5
Medium
Operational MOAT
✗ Below peers
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%+8.7% ★ Q1'26: +9.1% (vs Q1'25)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%+75.6% ★ Q1'26: +199.0% (vs Q1'25)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%+6.4% Q1'26: +15.9% (vs Q1'25)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%+26.9% ★ Q1'26: +26.7% (vs Q1'25)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%+13.6% ★ Q1'26: +13.3% (vs Q1'25)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%+0.3% Q1'26: +0.4% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×2.11× Q1'26: 2.15× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Mar 2018 actual |
Mar 2019 actual |
Mar 2020 actual |
Mar 2021 actual |
Mar 2022 actual |
Mar 2023 actual |
Mar 2024 actual |
Mar 2025 actual |
Mar 2026 9 Rev. Ana. 7 EPS Ana. |
Mar 2027 7 Rev. Ana. 7 EPS Ana. |
Mar 2028 10 Rev. Ana. 9 EPS Ana. |
Mar 2029 4 Rev. Ana. 3 EPS Ana. |
Mar 2030 3 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
8.27B
est: 8.53B (-3.0%)
|
9.67B
est: 9.90B (-2.3%)
|
10.58B
est: 10.66B (-0.7%)
|
11.93B
est: 12.07B (-1.1%)
|
13.26B
est: 13.44B (-1.4%)
|
16.62B
est: 16.89B (-1.6%)
|
19.91B
est: 22.47B (-11.4%)
|
28.79B
est: 29.58B (-2.6%)
|
32.24B
31.56B – 33.81B
+9.0% YoY
|
36.47B
35.35B – 37.39B
+13.1% YoY
|
41.38B
39.20B – 45.20B
+13.4% YoY
|
46.41B
46.33B – 46.48B
+12.2% YoY
|
52.00B
49.79B – 55.19B
+12.1% YoY
|
| EBITDA |
3.48B
est: 3.05B (+14.3%)
|
3.77B
est: 4.10B (-8.1%)
|
3.84B
est: 3.66B (+4.9%)
|
4.39B
est: 4.26B (+3.2%)
|
5.11B
est: 4.73B (+8.1%)
|
5.48B
est: 5.26B (+4.2%)
|
6.99B
est: 8.01B (-12.8%)
|
10.36B
est: 10.54B (-1.7%)
|
11.50B
11.26B – 12.06B
+9.1% YoY
|
13.01B
12.61B – 13.34B
+13.1% YoY
|
14.76B
13.98B – 16.12B
+13.4% YoY
|
16.55B
16.53B – 16.58B
+12.2% YoY
|
18.55B
17.76B – 19.69B
+12.1% YoY
|
| EBIT |
3.23B
est: 2.44B (+32.2%)
|
3.40B
est: 3.45B (-1.4%)
|
3.34B
est: 3.15B (+5.8%)
|
3.96B
est: 3.61B (+9.7%)
|
4.46B
est: 4.01B (+11.3%)
|
4.31B
est: 4.46B (-3.4%)
|
5.16B
est: 6.17B (-16.4%)
|
7.20B
est: 6.75B (+6.6%)
|
8.86B
8.67B – 9.29B
+31.1% YoY
|
10.02B
9.71B – 10.27B
+13.1% YoY
|
11.37B
10.77B – 12.42B
+13.4% YoY
|
12.75B
12.73B – 12.77B
+12.2% YoY
|
14.29B
13.68B – 15.16B
+12.1% YoY
|
| Net Income |
2.94B
est: 2.95B (-0.3%)
|
2.91B
est: 3.42B (-15.1%)
|
2.96B
est: 2.97B (-0.1%)
|
3.55B
est: 3.33B (+6.8%)
|
4.06B
est: 3.69B (+9.9%)
|
3.82B
est: 3.82B (-0.1%)
|
3.92B
est: 3.80B (+3.1%)
|
3.52B
est: 4.16B (-15.4%)
|
5.66B
5.13B – 6.18B
+36.1% YoY
|
6.35B
5.96B – 7.81B
+12.4% YoY
|
8.45B
7.04B – 10.03B
+33.0% YoY
|
9.54B
9.50B – 11.84B
+12.9% YoY
|
10.52B
9.94B – 11.36B
+10.3% YoY
|
| SGA |
2.03B
est: 1.30B (+55.7%)
|
2.45B
est: 4.48B (-45.2%)
|
2.32B
est: 4.80B (-51.8%)
|
2.44B
est: 5.74B (-57.5%)
|
2.62B
est: 6.37B (-58.9%)
|
3.55B
est: 7.09B (-50.0%)
|
4.14B
est: 4.55B (-8.9%)
|
5.26B
est: 8.80B (-40.2%)
|
6.52B
6.39B – 6.84B
-25.8% YoY
|
7.38B
7.15B – 7.57B
+13.1% YoY
|
8.37B
7.93B – 9.15B
+13.4% YoY
|
9.39B
9.38B – 9.41B
+12.2% YoY
|
10.52B
10.08B – 11.17B
+12.1% YoY
|
| EPS |
21.39
est: 21.64 (-1.1%)
|
21.15
est: 22.05 (-4.1%)
|
21.61
est: 21.89 (-1.3%)
|
26.16
est: 26.38 (-0.8%)
|
29.89
est: 30.55 (-2.2%)
|
28.10
est: 30.06 (-6.5%)
|
28.82
est: 27.96 (+3.1%)
|
25.85
est: 30.05 (-14.0%)
|
40.00
37.56 – 45.21
+33.1% YoY
|
50.88
43.62 – 57.11
+27.2% YoY
|
63.61
51.48 – 73.39
+25.0% YoY
|
77.98
69.50 – 86.60
+22.6% YoY
|
77.00
72.74 – 83.15
-1.3% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-25 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-05-22 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-05-21 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-05-20 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-19 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-18 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-15 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-14 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-13 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-12 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-11 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-08 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-07 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-06 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-05 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-04 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-30 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-29 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-28 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-27 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-24 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-23 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-22 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-21 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-20 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-17 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-16 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
2.16B
OE per share TTM
15.81
Owner's Yield
1.17%
Maintenance CapEx ratio
88.19%
Maint CapEx / Avg PPE
21.2%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
Held by 5 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Dimensional Emerging Markets Sustainability Core 1 ETF DFSE | 0.01% | 77.0K | 0.44% |
| 2 | Dimensional - Emerging Markets ex China Core Equity ETF DEXC | 0.01% | 37.3K | 0.56% |
| 3 | Dimensional - Emerging Core Equity Market ETF DFAE | 0.01% | 604.6K | 0.29% |
| 4 | Dimensional - Emerging Markets Core Equity 2 ETF DFEM | 0.01% | 545.3K | 0.39% |
| 5 | Dimensional World ex U.S. Core Equity 2 ETF DFAX | 0.00% | 453.9K | 0.28% |
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
No recent insider transactions.
Executive team
Top executives
EBIT / Employee
2.32M
Shares Outstanding
138.57M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Amit Indubhushan Bakshi | Chairman & MD | 49M | male |
| Krishnakumar Vaidyanathan | Executive Director & Chief Operating Officer | 46M | male |
| Kaushal Kamlesh Shah | Whole Time Director | 17M | male |
| Inderjeet Singh Negi | Executive Director | 12M | male |
| Milind Talegaonkar | Compliance Officer & Company Secretary | — | male |
| Murari Ranganathan | President of Cardiometabolic Business | — | male |
| Sachin Shah | Chief Financial Officer | — | male |
| Gagan Atreja | President of Sales & Marketing | — | male |
| Vijay S. Joshi | President of Medical | — | male |
| Deepak Kapoor | Senior Vice President | — | male |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for ERIS.NS
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
